ClinicalTrials.gg
Active, not recruitingNCT06641076IZAR-1Updated Nov 16, 2026

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug

A Phase 3 interventional study of Sonelokimab and Placebo in Arthritis, Psoriatic, sponsored by MoonLake Immunotherapeutics AG. Active, not recruiting at 182 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by MoonLake Immunotherapeutics AG · Phase 3, Interventional, and Treatment

Updated Oct 9, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
960
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 92 studies in Arthritis, Psoriatic with a site in Poland — 6 open to participants now, 25 under way, 18 of them phase 3. Arthritis, Psoriatic · Poland.

Planned enrollment
7th of 90
960 · median 399
Started
2024
with 5 others
Phase 3
61 of 92
3 open now
Primary completion
2026-05
later than 6 of 24 live
Registered
79th of 92
by date

Among the 92 studies in Arthritis, Psoriatic with a site in Poland, this one is the 7th largest by planned enrollment of the 90 interventional ones that give a count, is one of 6 that started in 2024, is one of 61 in phase 3, reaches primary completion later than 6 of the 24 other live ones, and was the 79th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

6 of the 92 studies in Arthritis, Psoriatic with a site in Poland are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies in Arthritis, Psoriatic with a site in Poland, or all of them as a file.
02

Study summary

This is a study to demonstrate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult patients with active psoriatic arthritis who are naive to biologic disease-modifying antirheumatic drug therapy.

Read the detailed description

M1095-PSA-301 is a Phase 3, multicenter, randomized, parallel-group, double-blind, 3-arm, placebo-controlled study to investigate the efficacy and safety of sonelokimab 60 mg every 4 weeks (with and without an induction regimen) versus placebo in adults with active psoriatic arthritis who are naive to biologic disease-modifying antirheumatic drug therapy.

03

Conditions studied

  • Arthritis, Psoriatic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must be ≥18 years of age .
  2. Participants have a confirmed diagnosis of psoriatic arthritis (PsA) per the 2006 Classification for Psoriatic Arthritis (CASPAR) criteria with symptoms for ≥6 months before the Screening Visit.
  3. Participants have active disease (defined by a 68 tender joint count [TJC68] of ≥3 and a 66 swollen joint count [SJC66] of ≥3).
  4. Participants have current active plaque psoriasis (PsO) or a dermatologist-confirmed history of plaque PsO.
  5. Participants test negative for both rheumatoid factor and anti-cyclic citrullinated peptide at the Screening Visit.

Exclusion criteria

Exclusion Criteria:

  1. Participants with a known to sonelokimab or any of its .
  2. Participants who have a diagnosis of chronic inflammatory conditions other than PsO or PsA.
  3. Participants with a diagnosis of inflammatory bowel disease.
  4. Participants who have experienced a period of ≥3 consecutive weeks of unexplained diarrhea in the 24 weeks before the Baseline Visit.
  5. Participants who have an established diagnosis of arthritis mutilans.
  6. Previous exposure to sonelokimab.
  7. Participants who have ever received any biologic immunomodulating agents for PsA or PsO, whether or approved.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
960 participants (estimated)

Study arms

  • Experimental
    sonelokimab dose with an induction regimen

    Subjects randomized to this arm will receive sonelokimab subcutaneously (SC) as an induction regimen of 4 doses, followed by sonelokimab SC every 4 weeks maintenance dosing starting at Week 8.

    Drug: Sonelokimab

  • Experimental
    sonelokimab dose without an induction regimen

    Subjects randomized to this arm will receive sonelokimab subcutaneously every 4 weeks.

    Drug: Sonelokimab

  • Placebo comparator
    Placebo

    Subjects randomized to this arm will receive placebo subcutaneously.

    Drug: Placebo

Interventions

  • Randomized treatment, parallel-group

  • DrugPlacebo

    Randomized treatment, parallel-group

06

What researchers measure

Primary outcomes

  1. Response rate of participants achieving at least a 50% improvement in the American College of Rheumatology criteria (ACR50)

    Proportion of participants achieving ACR50

    Time frame: Week 16

Secondary outcomes

  1. Response rate of participants achieving at least 20% improvement in the American College of Rheumatology criteria (ACR20)

    Proportion of participants achieving ACR20

    Time frame: Week 16

  2. Response rate of participants achieving Minimal Disease Activity (MDA)

    Proportion of participants achieving MDA

    Time frame: Week 16

  3. Health Assessment Questionnaire- Disability Index (HAQ-DI)

    Change in HAQ-DI from baseline

    Time frame: Week 16

  4. Psoriasis Area and Severity Index (PASI90)

    Proportion of participants achieving a decrease of ≥90% in the PASI90 response at Week 16 in the subgroup of participants with psoriasis (PsO) involving ≥3% body surface area at baseline

    Time frame: Week 16

  5. Short- form-36 (SF-36) Physical Component Summary (PCS)

    Change from Baseline in SF-36 PCS at Week 16

    Time frame: Week 16

  6. van der Heijde modified Total Sharp Score (vdHmTSS)

    Change from Baseline to Week 16 in joint/bone structural damage (vdHmTSS)

    Time frame: Week 16

07

Study locations

182 sites
  • Clinical Site
    Avondale, Arizona 85392, United States
  • Clinical Site
    Chandler, Arizona 85225, United States
  • Clinical Site
    Flagstaff, Arizona 86001, United States
  • Clinical Site
    Mesa, Arizona 85210, United States
  • Clinical Site
    Phoenix, Arizona 85032, United States
  • Clinical Site
    Scottsdale, Arizona 85260, United States
  • Clinical Site
    Tucson, Arizona 85748, United States
  • Clinical Site
    San Diego, California 92108, United States
  • Clinical Site
    Upland, California 91786, United States
  • Clinical Site
    Avon Park, Florida 33825, United States
  • Clinical Site
    Clearwater, Florida 33765, United States
  • Clinical Site
    Hialeah, Florida 33016, United States
  • Clinical Site
    Tampa, Florida 33607, United States
  • Clinical Site
    Springfield, Illinois 62702, United States
  • Clinical Site
    Lake Charles, Louisiana 70605, United States
  • Clinical Site
    Baltimore, Maryland 21224-6821, United States
  • Clinical Site
    Grand Blanc, Michigan 48439-2451, United States
  • Clinical Site
    Leland, North Carolina 28451, United States
  • Clinical Site
    Salisbury, North Carolina 28144, United States
  • Clinical Site
    Statesville, North Carolina 28625, United States
  • Clinical Site
    Middleburg Heights, Ohio 44130, United States
  • Clinical Site
    Portland, Oregon 97239, United States
  • Clinical Site
    Memphis, Tennessee 38119, United States
  • Clinical Site
    Allen, Texas 75013, United States
  • Clinical Site
    Colleyville, Texas 76034, United States
  • Clinical Site
    Lubbock, Texas 79424, United States
  • Clinical Site
    Plano, Texas 75024, United States
  • Clinical Site
    Beckley, West Virginia 25801, United States
  • Clinical Site
    Pleven, 5800, Bulgaria
  • Clinical Site
    Plovdiv, 4000, Bulgaria
  • Clinical Site
    Plovdiv, 4001, Bulgaria
  • Clinical Site
    Plovdiv, 4002, Bulgaria
  • Clinical Site
    Plovdiv, 4004, Bulgaria
  • Clinical Site
    Rousse, 7000, Bulgaria
  • Clinical Site
    Sofia, 1463, Bulgaria
  • Clinical Site
    Sofia, 1606, Bulgaria
  • Clinical Site
    Sofia, 1784, Bulgaria
  • Clinical Site
    Stara Zagora, 6003, Bulgaria
  • Clinical Site
    Calgary, T2N 4L7, Canada
  • Clinical Site
    Trois-Rivières, G9A 3X2, Canada
  • Clinical Site
    Waterloo, N2J 1C4, Canada
  • Clinical Site
    Winnipeg, R3A IM3, Canada
  • Clinical Site
    Rijeka, 51 000, Croatia
  • Clinical Site
    Zagreb, 10000, Croatia
  • Clinical Site
    Brno, 63800, Czechia
  • Clinical Site
    Břeclav, 690 02, Czechia
  • Clinical Site
    Ostrava, 70200, Czechia
  • Clinical Site
    Prague, 12850, Czechia
  • Clinical Site
    Prague, 140 00, Czechia
  • Clinical Site
    Prague, 140 59, Czechia
  • Clinical Site
    Prague, 14800, Czechia
  • Clinical Site
    Prague, 150 00, Czechia
  • Clinical Site
    Studénka, 742 13, Czechia
  • Clinical Site
    Zlín, 760 01, Czechia
  • Clinical Site
    Tallinn, 10117, Estonia
  • Clinical Site
    Tallinn, 13419, Estonia
  • Clinical Site
    Tartu, 50708, Estonia
  • Clinical Site
    Kuopio, 70100, Finland
  • Clinical Site
    Cahors, 46000, France
  • Clinical Site
    Caluire-et-Cuire, 69300, France
  • Clinical Site
    Échirolles, 38700, France
  • Clinical Site
    Montpellier, 34295, France
  • Clinical Site
    Narbonne, 11100, France
  • Clinical Site
    Nice, 06001, France
  • Clinical Site
    Rouen, 76031, France
  • Clinical Site
    Tours, 37170, France
  • Clinical Site
    Kutaisi, 4600, Georgia
  • Clinical Site
    Tbilisi, 0102, Georgia
  • Clinical Site
    Tbilisi, 0112, Georgia
  • Clinical Site
    Tbilisi, 0141, Georgia
  • Clinical Site
    Tbilisi, 0159, Georgia
  • Clinical Site
    Tbilisi, 0160, Georgia
  • Clinical Site
    Tbilisi, 0179, Georgia
  • Clinical Site
    Tbilisi, 0180, Georgia
  • Clinical Site
    Tbilisi, Georgia
  • Clinical Site
    Bad Bentheim, 48455, Germany
  • Clinical Site
    Berlin, 12161, Germany
  • Clinical Site
    Berlin, 12203, Germany
  • Clinical Site
    Berlin, 13125, Germany
  • Clinical Site
    Erlangen, 91054, Germany
  • Clinical Site
    Hamburg, 20095, Germany
  • Clinical Site
    Herne, 44649, Germany
  • Clinical Site
    Munich, 80639, Germany
  • Clinical Site
    Munich, 81667, Germany
  • Clinical Site
    München, 80336, Germany
  • Clinical Site
    Athens, Attica 11521, Greece
  • Clinical Site
    Athens, 12462, Greece
  • Clinical Site
    Heraklion, 71110, Greece
  • Clinical SIte
    Budapest, 1023, Hungary
  • Clinical Site
    Budapest, 1027, Hungary
  • Clinical Site
    Budapest, 1036, Hungary
  • Clinical Site
    Debrecen, H-4032, Hungary
  • Clinical Site
    Gyula, 5700, Hungary
  • Clinical Site
    Hódmezővásárhely, 6800, Hungary
  • Clinical Site
    Kalocsa, 6300, Hungary
  • Clinical Site
    Kistarcsa, 2143, Hungary
  • Clinical Site
    Nyíregyháza, 4400, Hungary
  • Clinical Site
    Székesfehérvár, 8000, Hungary
  • Clinical Site
    Veszprém, 8200, Hungary
  • Clinical Site
    Adazi, LV2164, Latvia

Showing the first 100 of 182 sites across 20 countries. Choose a country and city above to see the rest.

08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in May 2026, 19 months.

Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 19 months is below that.

Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.

Primary completion moved once since we started tracking on Sep 25, 2026: Feb 2027 → May 2026, on Oct 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2024
First posted
Oct 15, 2024
StartActual
Oct 15, 2024
Primary completionActual
May 28, 2026was Feb 2027
CompletionEst.
Feb 4, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Feb 4, 2027→May 28, 2026 (actual)
Oct 9, 2026
Show all 2 updates
  1. Nov 16, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 9, 2026
    Primary completion Feb 4, 2027→May 28, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06641076
Lead sponsor
MoonLake Immunotherapeutics AG
Responsible party
Sponsor
First posted
Oct 15, 2024
Start date
Oct 15, 2024
Primary completion
May 28, 2026
Completion
Feb 4, 2027 (estimated)
Last update
Nov 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sonelokimab

Start the discussion